Highlights Newsletter 2
This newsletter presents you the following key sessions:
1. Video-interview with Christopher Hourigan, MD, about the impact of conditioning intensity of allogeneic
transplantation for acute myeloid leukemia with genomic evidence of residual disease
2. Adding isatuximab to pomalidomide/dexamethasone significantly prolongs progression-free survival of
patients with relapsed/refractory multiple myeloma
3. Acalabrutinib delays disease progression in patients with relapsed/refractory chronic lymphocytic
leukemia
4. Adding venetoclax to bortezomib and dexamethasone worsens the overall survival of patients with
relapsed/refractory multiple myeloma
5. Overcoming the ‘don’t eat me signal’ in patients with refractory lymphoma